FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

Utah defines a Class D pharmacy as a nonresident pharmacy, meaning a pharmacy outside Utah that sells to a person in Utah, and requires a pharmacy license to act as a pharmacy. A Class D applicant must show a home-state license in good standing, a pharmacist-in-charge licensed in the state where the pharmacy is located (a Utah-licensed PIC is not required), background checks for pharmacy managers, and a pharmacy care protocol. A Class D pharmacy that compounds must submit its most recent inspection report, done within two years before applying, either through the NABP Verified Pharmacy Program or by its home-state board using the NABP multistate inspection blueprint. It must also follow USP <795> and <797>. The Utah Division of Professional Licensing (DOPL) enforces these rules with the Board of Pharmacy.

§58-17b-306 was amended by Laws 2026, Ch. 64, effective 7/1/2026. The two-year NABP VPP or blueprint inspection rule for compounders is in the current text. R156-17b-616 was last amended 11/25/2019 (Cornell copy), so it may be stale, although the statute is current. Controlled substances need a separate Utah Controlled Substance License.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

Utah Code §58-17b-624 allows a licensed pharmacy, subject to DOPL rules, to repackage or compound a prescription drug for sale to a practitioner for office use. The conditions are: a compounded drug may not be a controlled substance; it must be labeled 'for office use only'; the practitioner must give it in the office or facility; and the practitioner may not dispense it except as a licensed dispensing medical practitioner. The rule that implements the statute, R156-17b-624, allows this only when the pharmacy complies with all federal law, including the FD&C Act. In its May 2024 newsletter, the Utah Board of Pharmacy/DOPL said 503A office-use compounding 'is not allowed by law' and that a pharmacy would need to be a 503B outsourcing facility. DOPL has issued citations over compounded semaglutide distribution. In practice, Utah follows FDA's view that 503A compounding must be patient-specific.

The statute's text does allow office-use sales, but only under the federal-compliance condition in the rule. The Board's reading (May 2024) is that 503A office use is not allowed. That newsletter is about 2 years and 4 months old, so it is possibly stale; no later reversal was found. The statute has not changed since 7/1/2014.

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

Utah requires a license to act as a pharmacy (§58-17b-302). It defines a 'pharmaceutical facility' as a business dispensing, distributing, manufacturing or wholesaling prescription drugs 'within or into this state'. A Class C pharmacy is one that manufactures, produces, wholesales or distributes drugs in Utah. DOPL's Class C application takes out-of-state applicants (a Designated Representative, a home-state license and the latest state or NABP inspection), with Manufacturer and Distributor subtypes. A Class D license covers nonresident pharmacies that dispense to people in Utah. Neither the Utah statute nor the R156-17b rules mention 503B outsourcing facilities, so the exact class DOPL assigns to an out-of-state 503B is not written down.

That a license is required rests on the statute's text. Which class applies to a 503B (Class C Manufacturer, or Class D if patient-specific dispensing is also done) is an inference, because no Utah text names outsourcing facilities; confirm with DOPL at (801) 530-6628 / b3@utah.gov. The rule definition numbering (R156-17b-302) comes from a 2023 Cornell copy.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Utah is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

Utah Code 58-37-105(2)(a) requires every person who prescribes, dispenses or administers any Schedule I-V controlled substance in Utah to obtain a license from the Division, issued on a two-year renewal cycle set by rule, and 58-37-105(2)(e) requires a separate license at each principal place of business or professional practice where the licensee dispenses. DOPL states the controlled substance license is tied to a prescribing practitioner's license (e.g. physician or dentist) and is not a stand-alone license; holders of a prescribing license without a CS license apply through DOPL's licensing portal. Hospital medication orders are exempt from some prescription rules only when issued by a prescriber holding both an unrestricted DEA registration and an active Utah CS license (58-37-304(7)).

Utah's chapter 58-37 was renumbered in the version effective 7/1/2026: the CS licensing section appears as 58-37-105 (older materials cite it as 58-37-6). Fee and the order relative to DEA were not shown on the pages reviewed. DOPL may waive licensure by rule for some categories (58-37-105(2)(d)); medical residents may be exempt under 58-1-307(1)(c).

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

Utah Code Sec. 58-37f-304(2)(a) requires a prescriber to check the database before the first time the prescriber gives a patient a prescription for a Schedule II opioid or Schedule III opioid; under (2)(b), a prescriber repeatedly prescribing those opioids must periodically review the database or similar fill records. Employees may be assigned to do the check, and an approved EHR connection that prominently displays database data satisfies the duty. Failures caused by emergencies defined by rule, database outages or internet failures are not violations. The Division of Professional Licensing administers the database; non-opioid Schedule III drugs such as testosterone are outside the mandate.

Current version amended by Chapter 64, 2026 General Session, effective 7/1/2026. 'Schedule II opioid' and 'Schedule III opioid' are defined by reference to Utah Code 58-37-108. PDMP TTAC also lists Utah Code 26-61a-201 (medical cannabis) and 58-67-808/58-68-808.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

Under Utah Code 58-17b Part 8, a Dispensing Medical Practitioner licensed by DOPL and working with a dispensing medical practitioner clinic pharmacy may dispense cosmetic drugs and injectable weight-loss drugs listed by DOPL rule (not controlled substances), cancer regimens, and prepackaged drugs at employer clinics, and must tell patients they can use another pharmacy. Under Utah Code 58-88 (2022, amended 2026), a licensed dispensing practice may dispense prepackaged drugs only for conditions expected to last 30 days or less, evaluated the same day, up to a 30-day supply, never controlled substances, with written disclosure of the right to use a pharmacy. Testosterone cannot be dispensed under either route; GLP-1s only if on DOPL's injectable weight-loss list.

58-88 sections show amendments by Chapters 64 and 362, 2026 General Session (read from the current version served on 2026-09-23). The DOPL list of injectable weight-loss drugs was not reviewed.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

(1) A provider may not offer telehealth unless licensed under Utah Title 58 and in good standing; DOPL issues a temporary license authorizing telemedicine services to patients located in Utah to a holder of a nonresident license who has applied for a Utah license by endorsement when DOPL cannot process the application within 15 days (Utah Code 58-1-302.1). (2) There is no general in-person exam requirement: the Utah telehealth law applies in-person standards of practice, requires establishing a diagnosis from relevant clinical history before prescribing, and bars prescribing based solely on an online questionnaire, email or patient-generated history. (3) No Utah-specific telehealth limit on Schedule III drugs such as testosterone was found in these sources; federal controlled-substance rules apply. (4) IMLC: member.

Classified conditional only because of the telemedicine-specific temporary license (a bridge to full licensure, not a standing telehealth registration). Utah Controlled Substance rules were not separately reviewed for telehealth-specific limits; CCHP's Utah page (updated 2026-07-31) lists none for physicians. Cosmetic medical procedures require an in-person or live telemedicine evaluation before treatment (Utah Code 58-1-506, per CCHP).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

Utah Code §58-67-102 defines 'cosmetic medical procedure' to include the injection of a medication or substance, including a neurotoxin or filler, for cosmetic purposes. Under §58-1-506(3) (effective 2026-01-01), for nonablative cosmetic procedures other than hair removal a physician, NP or PA must develop a treatment plan and evaluate the patient in person or by live telemedicine before a treatment series begins; the supervisor (MD/DO or APRN) must authorize the procedure and provide general supervision (available in person for complications, within 60 minutes or 60 miles) for RNs, or direct supervision (present for face-to-face communication) for LPNs; delegates need training and documented competence (at least 80 hours under §58-1-506(2)(f)(iii)). The facility must post the supervisor's name and licence and give patients a 24-hour contact number. Delegates must also act within their own licensed scope.

Whether injections are 'nonablative procedures' for §58-1-506(3) is an interpretation: the statute defines nonablative procedures as those intended to alter living tissue without removing it, and lists injections as cosmetic medical procedures, but §58-1-506's text focuses on devices. The 80-hour competency list in (2)(f)(iii) is laser-oriented. Confirm with DOPL.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

Utah's cosmetic-procedure supervision law (§58-1-506) addresses cosmetic devices and cosmetic injections, not wellness IVs. The DOPL nursing page (checked 2026-09-23) had no IV-hydration guidance.

Check with DOPL (Board of Nursing / Physicians Licensing Board).

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Utah among non-CPOM states, citing the Utah Professional Corporation Act and Revised LLC Act, and MedPath Compliance (reviewed 2026-06-20) also lists Utah as 'No'. Utah's cosmetic-procedure statute nevertheless requires an MD/DO or APRN supervisor for each cosmetic medical facility's delegated procedures.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

Under §58-1-506, for nonablative laser hair removal the supervisor (MD/DO or APRN) writes the treatment plan, performs or delegates a pre-treatment 'hair removal review' to delegation group A (PA, RN, master esthetician, electrologist), and may delegate the procedure to group A under general supervision (available in person, within 60 minutes/60 miles) or to group B (LPN, esthetician, medical assistant) under indirect supervision (supervisor present in the facility). For other nonablative procedures (IPL, RF, lipolytic devices), a physician, NP or PA must evaluate the patient in person or by live telemedicine first, RNs and master estheticians need general supervision, and LPNs and estheticians need direct supervision. Delegates need at least 80 hours of documented laser/skin training plus CPR. Ablative procedures (e.g. CO2, erbium:YAG) are not covered by these delegation provisions.

Chiropractors with hair-removal training are exempt from these supervision rules for hair removal. Laser tattoo removal and cryolipolysis are excluded from the 'ablative' definition and tattoo removal from 'nonablative'.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Utah was not among them, but this research did not confirm its statutes. Utah's CLIA state agency is Utah Public Health Bureau of Laboratory Improvement (labimprovement@utah.gov, 801-538-4151); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Utah's rule. Utah's lab regulator (CLIA state agency) is Utah Public Health Bureau of Laboratory Improvement (labimprovement@utah.gov, 801-538-4151). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Utah Code §58-1-512 (enacted 2024, ch. 265, SB 199; amended by SB 55, effective May 6, 2026) covers 'stem cell therapy' using afterbirth placental perinatal stem cells or HCT/Ps (as defined in 21 CFR 1271.3), excluding abortion-derived tissue. A health care provider whose scope of practice includes stem cell therapy may perform non-FDA-approved therapy if it gives the patient the required written notice, posts it (8.5 x 11 inches, 40-point type), includes it in all advertising, and obtains signed consent covering FDA status, anticipated results, alternatives and risks. New in 2026: a person may supply HCT/Ps to a provider only after the provider gives the supplier written confirmation that it will give the notice to each patient. Providers with an FDA IND/IDE or working for FACT-, BMT CTN- or AABB-certified institutions are exempt. A violation is unprofessional conduct. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

Supplier duty: a marketplace or distributor shipping HCT/Ps (for example amniotic, placental or Wharton's jelly products) to a Utah provider needs that provider's written confirmation first. Because the HCT/P definition follows 21 CFR 1271.3, secreted products such as exosomes may fall outside it; not confirmed.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Utah does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.